Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, LONG-TERM SAFETY STUDY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP

NCT00960804 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00960804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00960804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, LONG-TERM SAFETY STUDY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
February 15, 2010
Completion date
November 11, 2010
Enrollment
21 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis